Strs Ohio Has $62.85 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Strs Ohio boosted its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.2% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 341,683 shares of the pharmaceutical company’s stock after purchasing an additional 578 shares during the quarter. Strs Ohio owned about 0.13% of Vertex Pharmaceuticals worth $62,852,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of VRTX. Resources Investment Advisors Inc. bought a new stake in Vertex Pharmaceuticals in the fourth quarter valued at approximately $27,000. We Are One Seven LLC bought a new stake in Vertex Pharmaceuticals in the fourth quarter valued at approximately $32,000. Berman Capital Advisors LLC bought a new stake in Vertex Pharmaceuticals in the fourth quarter valued at approximately $35,000. Sontag Advisory LLC bought a new stake in Vertex Pharmaceuticals in the fourth quarter valued at approximately $36,000. Finally, Quantamental Technologies LLC bought a new stake in Vertex Pharmaceuticals in the fourth quarter valued at approximately $41,000. 95.02% of the stock is owned by institutional investors and hedge funds.

Several analysts recently commented on VRTX shares. Zacks Investment Research upgraded Vertex Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, January 26th. Maxim Group cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, February 6th. They noted that the move was a valuation call. BMO Capital Markets upped their target price on Vertex Pharmaceuticals to $234.00 and gave the company an “outperform” rating in a report on Wednesday, February 6th. BidaskClub cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, February 7th. Finally, Cowen reiterated a “buy” rating and issued a $220.00 target price on shares of Vertex Pharmaceuticals in a report on Wednesday, March 6th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and fifteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $203.35.

In related news, CEO Jeffrey M. Leiden sold 20,997 shares of the stock in a transaction on Tuesday, February 19th. The stock was sold at an average price of $186.98, for a total value of $3,926,019.06. Following the completion of the sale, the chief executive officer now directly owns 110,095 shares of the company’s stock, valued at approximately $20,585,563.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Stuart A. Arbuckle sold 5,624 shares of the stock in a transaction on Monday, April 15th. The shares were sold at an average price of $181.75, for a total value of $1,022,162.00. Following the completion of the sale, the executive vice president now directly owns 36,272 shares of the company’s stock, valued at $6,592,436. The disclosure for this sale can be found here. Insiders sold a total of 209,487 shares of company stock valued at $37,734,043 over the last three months. 0.75% of the stock is currently owned by insiders.

Shares of NASDAQ:VRTX opened at $168.85 on Friday. The company has a current ratio of 3.78, a quick ratio of 3.66 and a debt-to-equity ratio of 0.13. Vertex Pharmaceuticals Incorporated has a twelve month low of $144.07 and a twelve month high of $195.81. The company has a market cap of $43.52 billion, a PE ratio of 59.66, a PEG ratio of 2.47 and a beta of 1.56.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Tuesday, April 30th. The pharmaceutical company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.49. Vertex Pharmaceuticals had a return on equity of 22.63% and a net margin of 66.01%. The company had revenue of $857.00 million for the quarter, compared to analyst estimates of $853.00 million. During the same period in the prior year, the firm earned $0.76 earnings per share. Vertex Pharmaceuticals’s revenue for the quarter was up 34.3% on a year-over-year basis. Equities analysts predict that Vertex Pharmaceuticals Incorporated will post 3.06 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Strs Ohio Has $62.85 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)” was first published by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/05/12/strs-ohio-grows-stake-in-vertex-pharmaceuticals-incorporated-vrtx.html.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.

See Also: Economic Reports

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.